OCGN - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Ocugen Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to Ken Inchausti, Head of Investor Relations and Communications for Ocugen. begin. may you Sir,

Ken Inchausti

for update, I'd will me welcome release CEO, today Musunuri, this Development, issued quarter XX available replay business also a Dr. operator. encourage and we full of Financial at and XXXX. conference update, of morning, a Head will and Ocugen results to a financial call. press is including We Shankar Corporate and business provide along for will to With financial which are www.ocugen.com. fourth presentation Subramanian, section slide on the who press our website be the like review you, Chief you a Officer who to Sanjay days. and accompanying our Co-Founder, being and recorded is provide listeners on Thank year a available Investor Ocugen's Earlier Chairman, website update. approximately with This release, call our the

ongoing the quarterly file the whether annual the will with are Commission, for and filings reports uncertainties and Biologics to that regulatory we Factors in this described risks results to These to whether to able and other from product always, the States that pandemic, actual risks risks for and the cause advise fully subject when our As including, among in could the the expectations, you and are Exchange contain other need periodic to License call forward-looking and differ including Such a statements Application our submit that more in Risk United risk Covaxin COVID-XX SEC. I to Canada. and in or factors regarding Covaxin uncertainties forward-looking the statements. will described entitled things, business research development uncertainty and when FDA, section candidates, we related we to with be the approvals inherent receive uncertainties in and of materially our Securities will

factors read our as should with and CEO, Shankar our will intend SEC. risks over on I in the press Musunuri. included file Chairman X. March in carefully described today's we release uncertainties and turn Ocugen's, call risk to filings Dr. the to that XX-K Form the You the as well now Note

Shankar Musunuri

Thank morning, and hope are and you for thank you, and Ken. you we Good well. your everyone, joining, safe family and

portfolio. time with as We XXXX you XXXX year highlights of the that product. on needs. later for milestones single us in game-changing of COVID year. so position most our Canada and a to much team review different challenges we phrase down NRX searching proud on partners Simultaneously, was diversified and business critical some purpose XXXX. especially that speaks activities a the our development perspective transformational gene our assets full a some commercial are and within progressed This recent our to trial clinical what today working here XXXX. Ocugen, Covaxin team enduring and with courageous we This and development, clinical in a has for into multiple succeeded purpose into innovation. genetic to of R&D and which for in that to US our I'm treat slide in initiating options new new more match of mutations two year this bring a part to solutions potentially for commitment to successfully therapy of expanded and could some with the great, to vaccine called the the a and the That double for fourth provide transpired I growing events a was quarter to on

for it's context made. we progress First, the the important understand to

on over submission late That how ongoing has strategies changed nation's We EUA early Last Licensing our clearance clinical gaps much to work and just IND the has evolved focus protection a is so paid closing in has meet among year, support work moment. submissions evolved BLA. from populations FDA that in science this to our October and we have That or our months remain In Today, the to to led off. one who have trial our the unvaccinated. Application, achieve initiate and oxygen, that the for week, a received November. to Biological seen have the changed. COVAXIN

program clinical immunobridging broadening and will Our X/X study. Phase be a

provide months the study will over progresses. more We as coming details the

submitted, discussions in On a the late Biotech’s have immunogenicity data XXXX. are involving data EUA Pediatric that, we there published say December front, Bharat the to in server including I'm pleased pre-print

than Our we know in the Omicron need more research in the XX% Harris of with COVAXIN of vaccinated looking teens Based latest XX for database variant with showing options. great. on own Poll, effectiveness India, Americans more million our this than against is

it evaluated as asking can't by known we many note Committee We move gives And asking recognize Vaccine two shot Independent you. the fair faster. ongoing will the and a continue have VRBPAC. would updates review advocating its having regulatory the FDA why that of by you Advisory things. hear been vaccine We for We

took The than took first with pleased it the is lifted. that, to three have I'm Clinical That the less Hold timeframe months.

the required have process. FDA. review details detrimental critical that, getting confidential juncture making been dialogue would to Therefore, the to public those is second with The significant the

questions is to us drug under contained what lead which review, Deficiency. the follow-up disclosed agency. Canada in to comprehensive responses review starts, as potentially will are once approval. is now the guidance new full of a we a known So COVAXIN until supplied clear In Notice little from Canada, Health set submission very of there from process be Remember, the is can that

nation's determined of middle and sense. establishing FDA made provide innovation and additional One BioSciences process, our manufacturing there's We at robust qualification primary to transfer quality capability are pleased public with standards manufacturing you product towards owned value involved with Health officials the up designing we this a in HollisterStier a provincial India year. speaking for there that is of complete meets local region, administered reestablishing on can is going and contribution, Canada a R&D the are we the site outside about supporting means that to Ontario. the Canada, interest selecting within make strategies health. about centered to following the will at government have establishing ad-direct growing Jubilant people. our establishing are and COVAXIN, The expect And final rigorous that by to manufacturing has to – Spokane, manufacturing Belleville, have active manufacturing that Jubilant interest grants and from safely nothing be and This well. partner leaders that of progress Positive And share we hub discussions note from control to the that assurance and and Washington. US, good final technology straight packaging of components transport ingredient Liminal by

to Now program. modifier therapy let's turn our gene

investigational you As, the of FDA gene clinicaltrials.gov. Institutes our the a Details know, we resulting submitted Pigmentosa lead for Within genetic dose for application from X/X and clinical ranging on National website, therapy now Rhodopsin. of platform and new of are application Retinitis recruiting. November available candidate trial drug our NrXeX clinical XX is accepted treatment days, Health OCUXXX, the an in our study trial a Phase in of XXXX, for the modifier mutations

is a Phase biologic, and well is that clinical potential our with and progressing OCUXXX to OCUXXX, candidate, next IND-enabling help study degeneration is transferrin-tumstatin underway future X/X has trial, age-related edema, support macular to with diabetic wet retinopathy, fusion activities. Our macular novel protein IND-enabling those diabetic

We toxicology are studies on to track non-human initiate primates. in

to key fast partners to with the year Sanjay submission on we the thank and provide two data for whose pleased our year know pediatric updates a with turn made. like year. is clinical COVAXIN, candidates continued XXXX I'm product now second for the remaining quarter very start FDA discussions financial surrounding with the to over XXXX of this I and off US have to readouts progress with our would will I expected full trials provide we Sanjay? call update. our our assets the portfolio. progress. to efforts our in progress the So half fourth that And throughout are ongoing

Sanjay Subramanian

and everyone. of the fourth now year and XXXX. of Shankar, financial overview good full I results will quarter morning for you, key an provide Thank

December quarter ended fourth development and the were XXXX for December $X.X the research Our ended $X.X quarter XX, XX, million, expenses for XXXX. compared million to

R&D quarter for and General the Biotech ended development our million for December is attributed development to additional for expenses were the a and quarter compared full $X.X XXXX. the research XXXX XXXX for The expenses expenses ended investment XX, to rights for upfront December ended the For and Administrative $X.X year, for and the year Canada. payment for XX, license to million increase included, to were million in the activities XXXX Bharat $XX in $XX.X XX, the fourth portfolio. to December ocular year compared COVAXIN $X.X ended COVAXIN remaining December million the XX, XXXX. continued million,

$X For $XX.X year the ended G&A for December to year full million XXXX compared XX, ended costs million, the XX, December were XXXX.

share relates to XXXX, December $X.XX share the loss $XX.X loss or $X.XX compared support years ended for December Net loss million to loss million quarter for approximately approximately quarter G&A in Our growth or was net XXXX. net increased per the to increase expenses infrastructure net of of XX, organization. $X.X costs XX, the the a ended per previous

the to asset Ocugen reported loss the as XXXX, or of previously XXXX, reduction in-process related the share a $X.XX million, approximately of net ended $X recorded loss share, for the million, held approximately $XX.X net net the expense of included or of year compared ended For XX, sale. December year carrying of net which to that million loss loss per was value XX, December $XX.X R&D for per an $X.XX

Our to update. offering sheet Ken. cash, week, to of this as million raised That Earlier XX, cash strengthens balance before compared $XX.X net of you, million concludes December equivalents $XX million XX, expenses. and totaled my further cash December extends This XXXX, proceeds $XX.X runway. we of our Back estimated XXXX. and our as restricted

Ken Inchausti

with Swayampakula first Instructions] question we from Wainwright. Ramakanth for the will line you. up open comes Thanks, Thank that, Sanjay. Operator? call H.C. of And the [Operator from questions. Our

Your line open. is

may go now ahead. You

Sanjay Subramanian

Yes. morning. Good

Operator

the We from question from have line another Zegbeh Jallah Capital ROTH of Partners.

is Your go Please open. ahead. line

Zegbeh Jallah

my the progress. taking questions for on Thanks congrats morning. and Good

lift the question first details you here was the can clinical the hold just required IND? what is to think I on comment the on me around if for

Sanjay Subramanian

Good morning, Zegbeh.

Shankar Musunuri

good Thanks Zegbeh, question. for morning. the

First submit it too extremely applications on FDA typically of on time. IND side. when vaccine busy many so the an FDA checked is The you as all,

everything and they we're call, process in whole which this within able have going mentioned they to we our they in I questions else considering So workload And months need. a promptly as questions, are the and responses, asked this and submitted up is our good FDA three typical those if wrap on. has, any is the clarifications

Zegbeh Jallah

can then And clarify. Thanks. you just

So of perhaps trying of pediatric any or data just a of additional that I'm the was reanalysis? that was that a EUA? to outcome sense needed it get predict just to kind

Shankar Musunuri

mean, let No, I me clarify think, IND on I hold. the

Additional are the second any so data Coming pediatric We is mostly. didn't was this clarification a questions asking to additional have data. to -- generate the EUA? not, question, you about

Zegbeh Jallah

just and based the what I cut EUA Yes. required IND. trying gauge on be for pediatric was the to might

that that So can. be well, if as that you you extent to can helpful the just comment on would

Shankar Musunuri

Yes.

trying large So for data India. in application process. we're with a biological generated in from the the to demographic data trial the IND U.S. licensing bridge is the long-term, clinical And

that's study X phase and that's and embarking we're on So for immuno-bridging broadening BLA.

based pediatric Authorization XX population, safety the to on our the Now, the bridges ages adults. data on trial, two data generated which submitted was for immuno-bridging trial to EUA scale large based in by Use partners, Emergency

that's under review PA. by active So

Zegbeh Jallah

you need they some a got just up, the then Thanks study we the out beyond investors, any studies approval on the additional as the bridging whether if kind to comes not wanted FDA meaning clarity follow positive, study that support and question committed this BLA of an bridging Shankar. And to approval? BLA the on from providing will

Shankar Musunuri

Yes.

the demographic Typically, bridges large bridging in scale scale that safety of That's trial. based efficacy what companies to have that One immuno-bridging. immunogenicity to on BLA are cannot the it the that's CFR, safety bridge the other the case side. trial. study the and efficacy kind conduct approval, think XX the trial. safety will because is we Typically, they keep have you large too, pediatric US BLA, population, Similarly, a for deal when a done safety bridge with the data for. from also bridging do do you apply with on and looks you on collected US, two Typically, efficacy in to population of for in elsewhere. US this there For and that you you are pediatric things in a I

foresee trial, the to addition safety doing a US in this population. trial immuno-bridging in we So

two those for typically clinical are the So BLA required trials submission.

Zegbeh Jallah

is to just bridging the provide Thanks, are a safety for And I assessments, there my your still upon here. here. for where just perhaps Perfect. need to bridging offering, study, prior wondering next public And determined, example, initiation the that then one now then Shankar. etcetera? this be of completed cash? was was for if the sample just comment can being study. or know last updated the regarding with I grade you can steps you size manufacturing Sanjay site last maybe And the but the we're squeezing recent study And

Shankar Musunuri

you typically for me so need population few take immunogenicity The subjects XXX study, bridging let the first Okay, trial. questions. for

so other the be population updates capture emergency antibodies. going requires the our that case, vaccine discussions And need on monitor. only not at because protein And are to have than Typically, looking that neutralizing also response, are more number, And spike-based providing we others to with Sanjay immune with safety agreement nuclear that will them, unlike be bridge. looking go we be provide market. need large ahead. there for You second FDA. a clinical antibodies bridges And those we'll ongoing question we'll this we spike, ask once vaccines. final broadening are is at then In don't the trial. does you on what

Sanjay Subramanian

question. the for Thanks

with financing it our week. strengthens we’re earlier and help programs even investment additional further. the pleased well did ocular this as all we The balance programs. sheet will a in cash as the that Covaxin our capital Regarding the

EUA the this pediatric Covaxin have we in time. pending for at for know, you use As point

there's term the that how So revenues. near potential potential, depending for progresses, upon

to go trials programs the that runway runway. and capital to we that obviously of ample well So that that, support raised, the contemplating any But have benefit have It our sufficient for the we’re we exclude in year. or have without we us into next gives our have-- all the cash the change capital we investment programs. we first we if from that, quarter and -- could that --

Zegbeh Jallah

I I'll do And into Sanjay. Thanks, get back about questions because the have OCUXXX. queue,

Sanjay Subramanian

thank Sure, you, Zegbeh. you. Thank

Operator

[Operator Instructions] Jallah have Zegbeh follow-up We from ROTH a from question Capital Partners.

open. Your Please line ahead. is go

Zegbeh Jallah

today. honors the asking of the have I all guess, questions I

it COVAXIN kind as on the here, I just think So moving question of the next relates opportunities. to

the can comment, of US having the market you late around surveyed who on that. and findings guess, maybe market. think And well about I perhaps, a being survey Just size as opportunity, of some you perhaps details the you and you bit on a kind comment of your the player to as then,

Shankar Musunuri

Yes.

Zegbeh, the continue market, still years. So few will US But pandemic, believe we we evolving, which is right? have next for the still

there's got So range significant no pediatric, vaccines group, the filed age five one the from vaccination a reason and are age the XX the have kids the five – currently, till two group, is only obviously, that we pediatric unmet XX that's available to doses XX%. need. And rates under -- who is EUA, medical there X about From available. vaccine option for

of and increase the effective. AgCom are there are great vaccination and So and rates, pediatric prevent important and to [ph] in have for need to which to the for amount pediatric options. looking safe that's populations, a datasets the requesting reason significant which agency vaccines hospitalization majority we And extremely for parents meeting. provided is push them the are death, And to

market. opportunity second so thing Second is is the -- booster

they'll vaccine, providing people this option an who the for technology and response, on boosters, know, or with relate such and ours, product be such also platform the immune to. got is for unvaccinated, the broadening And people looking you polio pandemic which eventually looking options. traditional they're as will who are As continue people can known vaccines, built as

such some of an get are vaccines. can there who hesitancy the And our vaccinated also vaccine not folks they to-date. option So are still who as

especially value. need to a have, for is the job with global are years US months at on vaccination of global at having efficacy and there people vaccine in vaccine safety. and from Unless certain Because that our toolkit, that, the US increase solid rates. And important multiple is vaccinated the vaccines be a has in refrigerator the a is which And purchasing it's believe, vaccine vaccine good temperature. diplomacy, companies, Therefore, a temperature, use. providing is is population will and extremely traditional can for significant provide shelf out there room a options six control. So not government to everywhere two to -- donating to of doing really addition we going also, platform vaccines options life this pandemic to the there built expected extent, under

for an stockpiling diplomacy and So, distribution. this for global will vaccine vaccine for ideal be vaccine

Zegbeh Jallah

some and that of that with do to Shankar, may the the Thanks advantage, an And what the thinking study? how but how really the kind terms think thinking would ask to in study being you plan within long how enroll help to you're you're helpful around timing comments perhaps about the of have of able around take? is that's strategies I position perhaps could how enrollment US even be about one you some then of guess you might

Shankar Musunuri

on clinical but allows I it there population, the after they and gap So, last think the trial allow can enrolled pause, they think on information shortly vaccinated, vaccine Covaxin is of a a I design, be clinicaltrials.gov is the that months who have but minimum study. named not only the will doses, subjects and trial posted got six study in

get after the great there's questions, on we'll to if and quickly I we lot will questions and trial. posted, we'll country. options creatively of very believe happy Zegbeh, clinicaltrials.gov and you this mean, And, be be in be from across have people for the country to very this So, further need able a calls we a address. again, have in details we designed its any recruit it posted And

Zegbeh Jallah

kind you'll sense quickly very Thanks just available? the the could do update? become data you at And And think detail to how of program, much study that we're next time wanting get interested a of OCUXXX you then in Shankar. just for of think when provide from

Shankar Musunuri

So, OCUXXX study is now. recruiting

If given. details are the clinicaltrials.gov, to you go

each. planning to patients we So, this in escalation. of and each is dose Phase trial mutations X/X nine it's two recruit a are mutation, Then

be patients. so to And able recruit those we'll

the is completing study. And this excited ongoing. main in recruitment very have second multiple and continue goal this this sites, for and process We in provide of we're year, the is identified half the year. Safety about the updates to

to looking through observation addition we'll efficacy that, In at be endpoints.

So, to half. we updates provide expect second in the

Zegbeh Jallah

about And in Thank this multiple able program the the key developing diseases. to use inherited to potential retinal be you. then it thing is

to And market sense be so able we are we to wondering, of you could opportunity just point on you the what I able for what going efficacy its be are this potential? And then get comment was blot at -- can program? think a again

Shankar Musunuri

Great Zegbeh. absolutely Yes, question.

good only the trials. not program. we the MLP-X, are mass itself, mean, into going Phase I thing our in this clinical that's So, about mutation X/X gene

robust modifier are also approach. into a mutation, looking We is which

covers opens for once RP working initiate those about you're -- activity envisioning CEPXXX that mutation is within So entire a patients, in show that door to is to Leber that talking amaurosis year. that And are patients covering actually in potentially, next we LCA, concept too population up of which is the mutation, hundreds we the it's Similar which congenital that there [indiscernible]. one within those RP.

mutations covering and which XXX two with struggled these Our globally least to LCA, goal covered, at diseases. three can patients mutations, these RP about represent million have is

a treat patients, has that's the and and population globally, So RP significant within US EU. XXX,XXX to these patients to lot about covering between and of XXX,XXX the enormous LC. US opportunity

size to are it's and who need. a would great moreover, a be So market huge them for -- these in patients it big desperate help rescue

do conference mid blind legally by XXs. mentioned calls, of become As patients I many they the past these time my in are

for There important. to can we sense these is needed really hope it's rescue be So urgency there them. We a of patients.

Zegbeh Jallah

Thanks Shankar, progress. congrats on and the

Shankar Musunuri

you. Thank

Sanjay Subramanian

Great. Thanks Zegbeh.

Operator

of line Our Brian from Cheng next question Cantor. comes from the

Please Your ahead. line go is open.

Brian Cheng

for the and guys. taking Hey Thanks on congrats my questions, progress.

near-term? the a manufacturing have pediatric assuming out and we perspective, them. and up COVAXIN? market reaching you just when vaccine I'm have on COVAXIN, for capacity And I the the the production capacity expect additional follow-up. think approval Can So will just part lastly, even speed do comment I unvaccinated and in a should have you hope about for capacity three that then question curious, And look And broad North supply subject? to to ramp-up to how the you America, can I Thanks. you from think answer partners the you for about

Shankar Musunuri

So, thank you. thank you Brian,

the capacity we progressing as let start mentioned with a will by is that me well, that it Jubilant plant runs. qualifying So Currently is really be call, question, UA HollisterStier mid-year is completing are authorized. on qualification I

However, partners what our inactivated in we and in is to release site up a they that are can product standards And capacity. established. packaging so in the the facilities, know, the done types testing needs US. have we established the in our already And have the Ocugen release we through plan, billion US it excel those this to vaccine, site, the interim, doses year have a India, to we as actually you scaled

immediately tested supply from initial will and in the the in So the to packaged US to US which release public. our gets come India, partners, from

for and product. million tech Jubilant ongoing, the good While capacity to to is planning does are XXX at we transfer up build

mentioned part, market, I the we use, the US aspects the the is as second before, of you envisioning; there third part are US global use one, bolster three are diplomacy. However, vaccine to supply pediatric in

purchasing So I mean abroad. distribution government for doses

the the second other they're the was question capacity be have government, done and completely to to now. is take of CMOs, distribution with supply and care whatever procurement our we'll building able and purchased unvaccinated. you done US, distribute And needs And the you also distribution, the with some the Currently, XXX% the states the as for reaching significant they So we're by partners that we believe own our capacity states They by related and is the in who people are. know, using are doses, the their network. they government.

So predicting, prioritization, may time the boasters all moves a have to time, and it annual gets we vaccines becomes we'll if and to is some an the work a by are details. all, know, certain And procured subjects obviously, endemic, therefore pandemic then governments, in future, option for others up. states many on now, government there and looking we'll you with But into when at government. this be you this to that the change, ever for, and are some if other states those because for know, distributed and have working obviously, are need, be you know, in happy vaccine, them

Brian Cheng

then ramp to ramp eventually thinking that product up outreach up the the partnership, of And population? actually even will one kind the adult think to do you you capacity? You're need on or on the about approval

Shankar Musunuri

vaccine needed. opportunistic. to our is know, you no, those we'll all are those goal as mean, I I be we'd of mean, options. all maximize, But this options supply Yes, exploring be

Brian Cheng

talk Okay. And you're that the about you can see targeting. just And, need other if are to then before Thanks, opportunity types? Shankar. know, Phase you running, with with expanding about you us or about you curious talk to one market mutation I'm what the will that mutations you to study OCUXXX. can on maybe initially X/X the size regards remind

Shankar Musunuri

mutation, check the study pick the as those you point trial a then Phase primary a a them to the observation objective others you you safety. year with once on mean, after trials multiple have year, one and months, three what Typical, primary X. clinical The it's trial, clinical into into for I my endpoints, you diseases. our therapy standard is every these because trial. into X/X follows exactly if for Phase in the make have a done. space is – this have And to have is mean, from look It's to done endpoints rare gene a one endpoint you I safety. look observational And typically, for observational monitor of the patients Yes,

Phase So maybe the go by means X Rhodopsin. to we this case, endpoint, that in primary than X different Phase time

before, Rhodopsin I modified as So, mentioned truly approach. follows

in methodically obviously, the Rhodopsin, work, for to do few have in to will is door supposed So part LCA. of be the RP, we clinical know, so the diseases. up many you opens rare working mutations, show signal that mutations. trials and And it's cognizant, I to if therefore, way mean, many, the a cover we also we the it's cover

just that, and know, although cover decline, limitations between So mentioned I this as before, you those LCA. RP XXX,XXX

than So the RPEXX-mutantation US, to XXX,XXX And I less X the size, is can and believe only populations, one it's Currently, RP look LCA between covering approved into patients. limitations. globally, and market there's XXX you about for has patients XXX,XXX million X,XXX those that in product US.

are the on for take And it. at they're a based you I the significant a So and companies there's look Brian, in products couple market. there, can pricing, other significant think pricing there And of gene therapy getting a I are unmet medical need, models. opportunity. and think a And similar

Brian Cheng

just terms other such into into slide see you you're also planning that mutation to I in because an other expand see to one need curious, you noticed expand efficacy, you do types, what need idea what of before to And as will well.

kind what other curious, investigated expand of expect just So should perhaps of bar type? before you which mutation in improvement sequential investors terms to

Shankar Musunuri

Yeah.

start – any we other to the product, CEPXXX, vaccine, so that So CEPXXX Brian, we data same and to in on study. the have with repeat it's we remember models, top don't do preclinical on for on wanted have

issue. And a it's timing so,

we that And broad is, EMA. Therefore, in also year, confident Phase then with our in RPA they'll into discussions X/X drug and what do are clinical on see, So we us we're the CEPXXX, mean, disease Since US, that. any We're who the four we're LCA, progression dose data for we we'll rescue, going after want the in and the those we'll broad believe you to coding agency see go the the we eventually, dose. and these orphan asking mutations have and potentially to And and touch getting believe endpoints do – actually how should Phase protecting three primary it's LCA is allow indications. LCA, to to with when one clinical into for are trials gene is into introduce we us issues EU. production. goal X. And with complete based the once least for at broad. this progression obviously, clinic therapy, articles clinic. the And single for and go into trials, I be to what actually into We're pick the has rescue, were from the EMA, people have go we and RPA the monitoring, in don't based communications endpoint obviously, allowed monitoring indications designations And us into mean, the the the CEPXXX. go hopefully, one disease I with you're on also we EMA. allow to in obviously, during while the process,

That's into Phase and carefully lot we'll be EU. together interface plan moving of between in and three for obviously, all collecting the cautiously mutations. X/X, So data a three US

the be on year, do the plan, endpoint, clinical the programs will Phase signal for So that primary EU the and based duration catch the X hope, Phase X X eventually, show, clinical one the to we trials. the you timeframe, trial. that's during the US also adequate for Phase continue we'll the Typically to mark and because have in

Brian Cheng

Shankar. next said, Thank to that you, your With forward looks update.

Shankar Musunuri

Yes. Welcome.

Sanjay Subramanian

Brian. you, Thank

Shankar Musunuri

Thank you.

Operator

time. are you questions further for continue remarks. Ken, may this no at there And closing

Ken Inchausti

providing in our on want we thank Bye. very the listen forward look a gene and And much. time both and have program, you who modified so we and to you took to the to the Thank much therapy in coming weekend. Thank great months. updates on call everybody, Great. COVAXIN

Operator

concludes Thank our does That today. all participating. conference for for you

day. You disconnect. may a now Have great

Ocugen (OCGN) 25 Feb 222021 Q4 Earnings call transcript